SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer and infectious diseases,
announced today that an IND (Investigational New Drug) application
for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell)
therapy has been filed with the U.S. Food and Drug
Administration.
This CAR-T therapy was invented by a team led by Dr.
Jose Conejo-Garcia, while he was at
the Wistar Institute. Dr. Conejo-Garcia is currently Chair of the
Department of Immunology at Moffitt Cancer Center (MCC), where the
IND enabling studies were performed, and where the clinical trial
will be conducted, under the leadership of Dr. Robert Wenham, Chair of Gynecological Oncology
at MCC. Anixa has a worldwide, exclusive commercial license to
the technology.
The technology targets the follicle stimulating hormone receptor
(FSHR) with engineered T-cells that use the follicle stimulating
hormone as a homing mechanism. FSHR is found at immunological
levels exclusively on the granulosa cells of the
ovaries. Since the target is a hormone receptor, this
technology is also known as CER-T (Chimeric Endocrine Receptor
T-cell) therapy, a new type of CAR-T.
Dr. Wenham stated, "We are pleased to file this IND application,
since women who have recurrent ovarian cancer have very few
options. We hope the work of our scientific and clinical team
at Anixa and MCC yields results that will address a critical unmet
medical need."
"We are looking forward to the response from the FDA, and to
eventually testing this therapy in humans," stated Dr.
Conejo-Garcia. "This is a very high-profile program at MCC, as
we believe this could be the first CAR-T therapy that has the
potential to achieve clinical success in a solid tumor
indication."
"This IND application is a major milestone for Anixa and our
partners at MCC," stated Dr. Amit
Kumar, President and CEO of Anixa Biosciences. "This is
our second IND application filed within the last few months. Upon
clearance from the FDA and commencement of the trial, we expect to
have two programs in the clinic."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutics portfolio includes a cancer immunotherapy program
which uses a novel type of CAR-T, known as chimeric endocrine
receptor T-cell (CER-T) technology, and a Covid-19 therapeutics
program focused on inhibiting certain viral protein
function. The company's vaccine portfolio includes a vaccine
to prevent breast cancer, and specifically triple negative breast
cancer (TNBC), the most deadly form of the disease, and a vaccine
to prevent ovarian cancer. These vaccine technologies focus on
immunizing against specific proteins that have been found to be
expressed in certain forms of cancer. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including, but not limited to, those concerning the progression of
the IND application for the ovarian cancer CAR-T therapy and
whether the ovarian cancer CAR-T therapy program will yield
positive results or achieve clinical success, and any other
of our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include,
but are not limited to, those factors set forth in "Item 1A - Risk
Factors" and other sections of our most recent Annual Report on
Form 10-K as well as in our Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. We undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as required by law. You are cautioned not to unduly rely on
such forward-looking statements when evaluating the information
presented in this press release.
Investor contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Media contact:
Sherry Ash
anixapress@gmail.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-and-moffitt-cancer-center-file-ind-application-for-ovarian-cancer-car-t-therapy-301252452.html
SOURCE Anixa Biosciences, Inc.